Download PDF
Digestive Disease Interventions
DOI: 10.1055/s-0045-1805052
Invited Article

Biliary Tract Cancer: Current Roles of Radiation Therapy

Kyle C. Cuneo 
1   Department of Radiation Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
,
Oxana V. Crysler
2   Division of Medical Oncology, Departments of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
,
Thomas Enzler
2   Division of Medical Oncology, Departments of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan
› Author Affiliations Funding This study was funded by NIH grant.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Biliary tract cancers, encompassing gallbladder cancer, intrahepatic cholangiocarcinoma (IHCC), and extrahepatic cholangiocarcinoma (EHCC), are rare malignancies with limited prospective studies guiding their management. Radiation therapy has evolved significantly over the years, advancing from conventional fractionated approaches to innovative modalities such as stereotactic body radiation therapy (SBRT) and hypofractionated radiation therapy. This review explores the role of radiation therapy in biliary tract cancers, with a particular focus on IHCC and EHCC, highlighting its historical evolution, current applications, and future directions. For IHCC, external beam radiation therapy has demonstrated benefits in retrospective analyses, with modern conformal techniques such as intensity-modulated radiation therapy and volumetric modulated arc therapy enabling safe dose escalation and improved local control. SBRT and hypofractionated radiation therapy offer promising alternatives for unresectable or recurrent IHCC, with high local control rates and manageable toxicity profiles reported in retrospective and early-phase prospective studies. Despite these advancements, the need for robust phase III comparative trials remains critical. In EHCC, radiation therapy plays a pivotal role in adjuvant and definitive settings. Additionally, radiation therapy is increasingly utilized as part of neoadjuvant protocols for liver transplantation candidates with unresectable hilar cholangiocarcinoma, improving outcomes when combined with strict selection criteria and modern systemic therapies. This review underscores the importance of a multidisciplinary approach to the management of biliary tract cancers, integrating radiation therapy advancements with systemic and surgical therapies. Future research should focus on personalized treatment strategies, leveraging novel technologies and biomarker-driven approaches to optimize outcomes for this challenging patient population.

Keywords

cholangiocarcinoma - radiation therapy - stereotactic body radiation therapy - biliary tract cancer


Publication History

Received: 28 January 2025

Accepted: 11 February 2025

Article published online:
05 March 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [published correction appears in CA. Cancer J Clin. 2024; 74 (02) 203
    PubMedSearch in Google Scholar
  • 2 Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist 2016; 21 (05) 594-599
    CrossrefPubMedSearch in Google Scholar
  • 3 Mukkamalla SKR, Naseri HM, Kim BM, Katz SC, Armenio VA. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Canc Netw 2018; 16 (04) 370-376
    CrossrefPubMedSearch in Google Scholar
  • 4 Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol 2020; 72 (01) 95-103
    CrossrefPubMedSearch in Google Scholar
  • 5 Nathan H, Aloia TA, Vauthey JN. et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16 (01) 14-22
    CrossrefPubMedSearch in Google Scholar
  • 6 Carpizo DR, D'Angelica M. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2009; 18 (02) 289-305 , viii–ix
    CrossrefPubMedSearch in Google Scholar
  • 7 Primrose JN, Fox RP, Palmer DH. et al; BILCAP Study Group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019; 20 (05) 663-673
    CrossrefPubMedSearch in Google Scholar
  • 8 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60 (06) 1268-1289
    CrossrefPubMedSearch in Google Scholar
  • 9 Referenced with Permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancers V.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed December 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org
    PubMed
  • 10 Valle J, Wasan H, Palmer DH. et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
    CrossrefPubMedSearch in Google Scholar
  • 11 Kelley RK, Ueno M, Yoo C. et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10391): 1853-1865
    CrossrefPubMedSearch in Google Scholar
  • 12 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) a2200015
    PubMedSearch in Google Scholar
  • 13 Lamarca A, Palmer DH, Wasan HS. et al; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 2021; 22 (05) 690-701
    CrossrefPubMedSearch in Google Scholar
  • 14 Cuneo KC, Herr DJ. Advances in radiation therapy for primary liver cancer. Surg Oncol Clin N Am 2023; 32 (03) 415-432
    CrossrefPubMedSearch in Google Scholar
  • 15 Crane CH, Macdonald KO, Vauthey JN. et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002; 53 (04) 969-974
    CrossrefPubMedSearch in Google Scholar
  • 16 Pan CC, Kavanagh BD, Dawson LA. et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76 (3, Suppl): S94-S100
    CrossrefPubMedSearch in Google Scholar
  • 17 Jackson MW, Amini A, Jones BL, Rusthoven CG, Schefter TE, Goodman KA. Treatment selection and survival outcomes with and without radiation for unresectable, localized intrahepatic cholangiocarcinoma. Cancer J 2016; 22 (04) 237-242
    CrossrefPubMedSearch in Google Scholar
  • 18 Shinohara ET, Mitra N, Guo M, Metz JM. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008; 72 (05) 1495-1501
    CrossrefPubMedSearch in Google Scholar
  • 19 Chen YX, Zeng ZC, Tang ZY. et al. Determining the role of external beam radiotherapy in unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 84 patients. BMC Cancer 2010; 10: 492
    CrossrefPubMedSearch in Google Scholar
  • 20 Zeng ZC, Tang ZY, Fan J. et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J 2006; 12 (02) 113-122
    PubMedSearch in Google Scholar
  • 21 Phelip JM, Vendrely V, Rostain F. et al. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study. Eur J Cancer 2014; 50 (17) 2975-2982
    CrossrefPubMedSearch in Google Scholar
  • 22 Yu Q, Liu C, Pillai A, Ahmed O. Twenty years of radiation therapy of unresectable intrahepatic cholangiocarcinoma: internal or external? A systematic review and meta-analysis. Liver Cancer 2021; 10 (05) 433-450
    CrossrefPubMedSearch in Google Scholar
  • 23 Apisarnthanarax S, Barry A, Cao M. et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol 2022; 12 (01) 28-51
    CrossrefPubMedSearch in Google Scholar
  • 24 Tse RV, Hawkins M, Lockwood G. et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. [published correction appears in J Clin Oncol. 2008 Aug 10;26(23):3911–2] J Clin Oncol 2008; 26 (04) 657-664
    CrossrefPubMedSearch in Google Scholar
  • 25 Weiner AA, Olsen J, Ma D. et al. Stereotactic body radiotherapy for primary hepatic malignancies - report of a phase I/II institutional study. Radiother Oncol 2016; 121 (01) 79-85
    CrossrefPubMedSearch in Google Scholar
  • 26 Hawkins MA, Valle JW, Wasan HS. et al. Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): results from a randomized phase II trial. J Clin Oncol 2024; 42 (S16): 4006
    CrossrefPubMedSearch in Google Scholar
  • 27 Mahadevan A, Dagoglu N, Mancias J. et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma. J Cancer 2015; 6 (11) 1099-1104
    CrossrefPubMedSearch in Google Scholar
  • 28 Kozak MM, Toesca DAS, von Eyben R, Pollom EL, Chang DT. Stereotactic body radiation therapy for cholangiocarcinoma: optimizing locoregional control with elective nodal irradiation. Adv Radiat Oncol 2019; 5 (01) 77-84
    CrossrefPubMedSearch in Google Scholar
  • 29 Brunner TB, Blanck O, Lewitzki V. et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiother Oncol 2019; 132: 42-47
    CrossrefPubMedSearch in Google Scholar
  • 30 Shen ZT, Zhou H, Li AM, Li B, Shen JS, Zhu XX. Clinical outcomes and prognostic factors of stereotactic body radiation therapy for intrahepatic cholangiocarcinoma. Oncotarget 2017; 8 (55) 93541-93550
    CrossrefPubMedSearch in Google Scholar
  • 31 Sebastian NT, Tan Y, Miller ED, Williams TM, Alexandra Diaz D. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma. Clin Transl Radiat Oncol 2019; 19: 66-71
    CrossrefPubMedSearch in Google Scholar
  • 32 Barney BM, Olivier KR, Miller RC, Haddock MG. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 2012; 7: 67
    CrossrefPubMedSearch in Google Scholar
  • 33 Jung DH, Kim MS, Cho CK. et al. Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma. Radiat Oncol J 2014; 32 (03) 163-169
    CrossrefPubMedSearch in Google Scholar
  • 34 Gkika E, Hallauer L, Kirste S. et al. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer 2017; 17 (01) 781
    CrossrefPubMedSearch in Google Scholar
  • 35 Tao R, Krishnan S, Bhosale PR. et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis. J Clin Oncol 2016; 34 (03) 219-226
    CrossrefPubMedSearch in Google Scholar
  • 36 Smart AC, Goyal L, Horick N. et al. Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020; 27 (04) 1122-1129
    CrossrefPubMedSearch in Google Scholar
  • 37 Ben-Josef E, Guthrie KA, El-Khoueiry AB. et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 2015; 33 (24) 2617-2622
    CrossrefPubMedSearch in Google Scholar
  • 38 Dominguez DA, Wong P, Chen YJ. et al. Adjuvant chemoradiation in resected biliary adenocarcinoma: evaluation of SWOG S0809 with a large national database. Ann Surg Oncol 2024; 31 (08) 4896-4904
    CrossrefPubMedSearch in Google Scholar
  • 39 Hughes MA, Frassica DA, Yeo CJ. et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007; 68 (01) 178-182
    CrossrefPubMedSearch in Google Scholar
  • 40 Nelson JW, Ghafoori AP, Willett CG. et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2009; 73 (01) 148-153
    CrossrefPubMedSearch in Google Scholar
  • 41 Kim TH, Han SS, Park SJ. et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys 2011; 81 (05) e853-e859
    CrossrefPubMedSearch in Google Scholar
  • 42 Lim KH, Oh DY, Chie EK. et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study. BMC Cancer 2009; 9: 345
    CrossrefPubMedSearch in Google Scholar
  • 43 De Vreede I, Steers JL, Burch PA. et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma. Liver Transpl 2000; 6 (03) 309-316
    CrossrefPubMedSearch in Google Scholar
  • 44 Azad AI, Rosen CB, Taner T, Heimbach JK, Gores GJ. Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation. Cancers (Basel) 2020; 12 (11) 3157
    CrossrefPubMedSearch in Google Scholar
  • 45 Darwish Murad S, Kim WR, Harnois DM. et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 2012; 143 (01) 88-98 .e3, quiz e14
    CrossrefPubMedSearch in Google Scholar
  • 46 Panjala C, Nguyen JH, Al-Hajjaj AN. et al. Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma. Liver Transpl 2012; 18 (05) 594-601
    CrossrefPubMedSearch in Google Scholar
  • 47 Duignan S, Maguire D, Ravichand CS. et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience. HPB (Oxford) 2014; 16 (01) 91-98
    CrossrefPubMedSearch in Google Scholar
  • 48 Welling TH, Feng M, Wan S. et al. Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma. Liver Transpl 2014; 20 (01) 81-88
    CrossrefPubMedSearch in Google Scholar